J.P. Morgan Bangs the Drum on These 2 ‘Strong Buy’ Stocks

Company Overview - Oculis is a Swiss-based biopharma company focused on improving eye care and saving patients' vision, with operations in the US and Iceland [2] - The company has developed a differentiated pipeline of drug candidates for conditions such as diabetic macular edema (DME) and acute optic neuritis (AON) [2] Pipeline and Drug Candidates - Oculis has several late-stage clinical studies, including OCS-01, a potential treatment for DME, which affects over 37 million people globally, projected to rise to 53 million by 2040 [1][2] - OCS-01 is the first topical eye drop for DME, with two fully enrolled Phase 3 trials (DIAMOND) involving over 800 patients, and topline data expected in 2Q26 [7][10] - The company plans to submit a New Drug Application (NDA) to the FDA in 2H26, with the DME market estimated at $5 billion globally [7][10] - Oculis is also developing privosegtor (OCS-05) for AON and NAION, with several clinical trials underway, including positive results from Phase 2 trials [8][11] Financial Position - As of the end of Q3, Oculis had $182.2 million in cash and liquid assets, which increased to $300 million following a capital raise campaign in October [9] Analyst Insights - Analysts view Oculis as offering a diversified ophthalmology pipeline with high unmet needs, particularly for DME with OCS-01 showing promising efficacy and safety [10] - The stock has received a Strong Buy consensus rating, with a price target of $38 indicating an 81% upside potential, while the current stock price is $20.97 [11]